Acasti Pharma Inc (ACST)
2.90
-0.03
(-0.97%)
USD |
NASDAQ |
Apr 26, 16:00
2.92
+0.02
(+0.69%)
After-Hours: 20:00
Acasti Pharma Cash from Financing (TTM): 7.359M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 7.359M |
September 30, 2023 | 7.359M |
June 30, 2023 | 0.109M |
March 31, 2023 | 0.304M |
December 31, 2022 | 0.304M |
September 30, 2022 | 0.304M |
June 30, 2022 | 0.195M |
March 31, 2022 | 0.00 |
December 31, 2021 | 34.68M |
September 30, 2021 | 54.42M |
June 30, 2021 | 57.86M |
March 31, 2021 | 59.49M |
December 31, 2020 | 24.28M |
September 30, 2020 | 11.65M |
June 30, 2020 | 14.78M |
March 31, 2020 | 13.18M |
December 31, 2019 | 15.83M |
September 30, 2019 | 44.31M |
June 30, 2019 | 37.79M |
March 31, 2019 | 45.69M |
December 31, 2018 | 43.30M |
September 30, 2018 | 17.15M |
June 30, 2018 | 17.09M |
March 31, 2018 | 8.832M |
December 31, 2017 | 9.099M |
Date | Value |
---|---|
September 30, 2017 | -0.3421M |
June 30, 2017 | -0.3356M |
November 30, 2016 | -0.0123M |
August 31, 2016 | -0.0126M |
May 31, 2016 | -0.0114M |
February 29, 2016 | -0.0022M |
November 30, 2015 | -0.0062M |
August 31, 2015 | -0.0085M |
May 31, 2015 | -0.0099M |
February 28, 2015 | 0.0368M |
November 30, 2014 | 21.59M |
August 31, 2014 | 22.10M |
May 31, 2014 | 22.46M |
February 28, 2014 | 22.44M |
November 30, 2013 | 1.065M |
August 31, 2013 | 0.566M |
May 31, 2013 | 0.2283M |
February 28, 2013 | 0.2215M |
November 30, 2012 | 2.330M |
August 31, 2012 | 9.944M |
May 31, 2012 | 9.954M |
February 29, 2012 | 9.941M |
November 30, 2011 | 7.832M |
August 31, 2011 | 4.431M |
May 31, 2011 | 4.395M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
Mar 2022
59.49M
Maximum
Mar 2021
20.22M
Average
13.18M
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
Aurinia Pharmaceuticals Inc | -5.13M |
Edesa Biotech Inc | 2.224M |
Lexaria Bioscience Corp | 6.862M |
Xenon Pharmaceuticals Inc | 353.52M |
ESSA Pharma Inc | 0.1129M |